01—Abstract
Summary
Summary of the 10-K filed February 6, 2020. Cited figures are marked; the original filing is the authoritative source.
3M Company's 2019 10-K filing reveals a challenging year marked by a decline in net sales and net income, largely attributed to softness in key end markets such as automotive and electronics, coupled with channel inventory adjustments, particularly in the Asia Pacific region.
The company experienced impacts from restructuring actions taken in the second and fourth quarters to address lower sales volumes and realign its organizational structure for improved growth and efficiency. Despite these headwinds, the Health Care and Consumer segments demonstrated sales growth. The company continued its strategic acquisitions, notably Acelity Inc., to bolster its Health Care segment, and also divested certain non-core businesses.
Significant litigation-related charges, particularly concerning PFAS matters, impacted results, leading management to provide "adjusted" non-GAAP financial measures to offer insights into underlying operational trends. Looking ahead, 3M highlighted its ongoing commitment to strategic capital deployment, including investments in R&D and complementary acquisitions, alongside returning cash to shareholders through dividends and share repurchases.
The company's financial condition remains stable with strong operating cash flow, though increased debt levels were noted, primarily related to recent acquisitions and financing activities. Management anticipates continued focus on productivity improvements and navigating global economic and regulatory landscapes.
02—Key points
Key Highlights
- Net sales decreased by 1.9% to $32.1 billion in 2019, impacted by declines in Safety and Industrial and Transportation and Electronics segments.
- Net income attributable to 3M decreased by 12.1% to $4.6 billion, or $7.81 per diluted share, in 2019.
- Significant litigation-related charges, including $762 million pre-tax for PFAS and coal mine dust respirator mask lawsuits, negatively impacted earnings.
- The Health Care segment showed robust sales growth of 8.9% organically, driven by acquisitions and strong performance in Medical Solutions and Health Information Systems.
- Restructuring actions were taken in Q2 and Q4 2019, resulting in pre-tax charges of $282 million, aimed at improving efficiency and aligning the organization.
- 3M completed significant acquisitions in 2019, including Acelity Inc. for $4.5 billion (net of cash acquired), enhancing its Health Care business.
- Operating cash flow increased by 9.8% to $7.1 billion in 2019, primarily due to the timing of litigation-related payments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, 3M Co kept $0.14.
- Revenue$32.14B100.0%
- Cost of revenue−$17.14B53.3%
- Gross profit$15.00B46.7%
- Operating costs−$8.83B27.5%
- Operating income$6.17B19.2%
- Interest, other & tax−$1.66B5.2%
- Net income$4.52B14.1%
Where FY2019 revenue went
$32.14B- Cost of revenue: $17.14B, 53% of revenue
- SG&A: $7.03B, 22% of revenue
- Net income: $4.52B, 14% of revenue
- R&D: $1.25B, 3.9% of revenue
- Other operating costs: $544.0M, 1.7% of revenue
- Interest, other & tax: $1.66B, 5.2% of revenue
Kept 14% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 6, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $32.14B$32.77B | −1.9% |
| Cost of Revenue | $17.14B$16.68B | +2.7% |
| Gross Profit | $15.00B$16.08B | −6.7% |
| R&D Expenses | $1.25B$1.25B | 0.0% |
| SG&A Expenses | $7.03B$7.60B | −7.5% |
| Operating Expenses | $25.96B$25.56B | +1.6% |
| Operating Income | $6.17B$7.21B | −14.3% |
| Interest Expense | $448.00M$350.00M | +28.0% |
| Net Income | $4.52B$5.35B | −15.6% |
| EPS (Basic) | $7.83$9.09 | −13.9% |
| EPS (Diluted) | $7.72$8.89 | −13.2% |
| Shares Outstanding (Basic) | 577.00M588.50M | −2.0% |
| Shares Outstanding (Diluted) | 585.10M602.00M | −2.8% |
05—Questions
Frequently Asked Questions
What were the primary drivers of 3M's financial performance in 2019?
3M's financial performance in 2019 was primarily driven by a decrease in net sales, particularly in the Safety and Industrial and Transportation and Electronics segments, due to softness in end markets like automotive and electronics, and channel inventory adjustments. Significant litigation-related charges, especially concerning PFAS matters, also impacted net income. Restructuring actions were undertaken to address lower sales volumes and improve operational efficiency. The Health Care and Consumer segments showed resilience with sales growth.
How did the company address its challenging market conditions and operational issues?
3M implemented restructuring actions in the second and fourth quarters of 2019, impacting approximately 3,500 positions globally. These actions were aimed at realigning the organizational structure and operating model to improve growth and operational efficiency. The company also focused on productivity projects to mitigate the impact of raw material price inflation and supply challenges.
What is the company's outlook and strategy for growth?
3M's strategy involves continued investment in its businesses to drive organic growth, complemented by strategic acquisitions. The company also remains committed to returning cash to shareholders through dividends and share repurchases. Management expects to continue investing in R&D and commercialization capabilities to support future growth.
How significant are the litigation-related charges, particularly those related to PFAS?
Litigation-related charges, especially concerning PFAS (per- and polyfluoroalkyl substances) and coal mine dust respirator mask lawsuits, were significant in 2019, amounting to $762 million pre-tax. These charges, along with a charge for the deconsolidation of its Venezuelan subsidiary, negatively impacted the company's reported net income and earnings per share. 3M uses adjusted non-GAAP measures to provide a clearer view of ongoing operational performance.
06—Continue